Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date09 Nov 2021 |
银翘败毒片治疗感冒(外感风热证)安全性和有效性随机双盲、阳性药、安慰剂平行对照、多中心Ⅲ期临床试验
[Translation] A randomized, double-blind, positive drug, placebo-controlled, multicenter phase III clinical trial on the safety and efficacy of Yinqiao Baidu Tablets in the treatment of colds (exogenous wind-heat syndrome)
进一步评价银翘败毒片治疗外感风热所致的感冒的有效性和安全性。
[Translation] To further evaluate the effectiveness and safety of Yinqiao Baidu Tablets in treating colds caused by exogenous wind-heat.
100 Clinical Results associated with Beijing Tianlizhengyuan Pharmaceutical Technology Development Co., Ltd.
0 Patents (Medical) associated with Beijing Tianlizhengyuan Pharmaceutical Technology Development Co., Ltd.
100 Deals associated with Beijing Tianlizhengyuan Pharmaceutical Technology Development Co., Ltd.
100 Translational Medicine associated with Beijing Tianlizhengyuan Pharmaceutical Technology Development Co., Ltd.